SEC Filings

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

Filing date Form Description Filing Group View
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Registration Statements
View HTML
D

Notice of Exempt Offering of Securities, item 06b

Other
View HTML
D
Other
View HTML
D
Other
View HTML

Data provided by Kaleidoscope.